CAGR oncology biomarker clinical trials by cancer type worldwide 2000-2018

Veuillez noter que la page demandée n’est pas disponible dans la langue par défaut sélectionnée. Vous utilisez notre plateforme dans une autre langue maintenant.

This statistic depicts the compound annual growth rate (CAGR) of oncology biomarker clinical trials started worldwide between 2000 and 2018, by cancer type. During these years, brain/glioma/CNS cancer clinical trials had the highest CAGR of 25.1 percent, followed closely by lung cancer clinical trials with a CAGR of 24.9 percent.

CAGR of oncology biomarker clinical trials worldwide from 2000 to 2018, by cancer type*

Type of cancer	Compound annual growth rate (2000-2018)
Brain/glioma/CNS	25.1%
Lung	24.9%
Stomach	24.3%
Head and neck	23%
Melanoma	22.4%
Renal	21.6%
Potential pan-tumor**	21.2%
Colorectal	21.1%
Ovarian	19%
Myeloma	15.8%
Breast	14%
Pancreatic	13%
Lymphoma	12.6%
Leukemia	12.4%
Prostate	11.4%
Myelodysplastic syndromes (MDS)	11.2%

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

November 2019

More information

Region

Worldwide

Survey time period

2000 to 2018

Supplementary notes

* Trials looking at two or more indications are repeat counted for each indication.
** Potential pan-tumor biomarker trials were determined based on a proxy of trial activity that could potentially lead to a pan-tumor label and included oncology biomarker clinical trials in Phase 2,3 or 4 with >five specified tumors per trial or

Citation formats